| Serotonin Transporter (SERT) | |
|---|---|
| Gene | SLC6A4 |
| Protein | Serotonin transporter |
| Location | Plasma membrane |
| Function | Serotonin reuptake |
| Brain Regions | Raphe nuclei, terminals |
| Drug Target | SSRIs, TCAs |
The serotonin transporter (SERT), encoded by the SLC6A4 gene, is a plasma membrane protein responsible for the high-affinity reuptake of serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft back into presynaptic neurons[1]. This transporter is a critical component of serotonergic neurotransmission, terminating synaptic signaling and maintaining serotonin homeostasis in the brain. SERT is the primary molecular target for selective serotonin reuptake inhibitors (SSRIs), the most widely prescribed class of antidepressant medications[2].
SERT is expressed predominantly in serotonergic neurons of the raphe nuclei and their projection regions throughout the brain[3]. It is also expressed in peripheral tissues including platelets, gut, and lungs. The functional regulation of SERT involves complex mechanisms including phosphorylation, trafficking, and protein-protein interactions that modulate its activity and cell surface expression[4].
The human SLC6A4 gene is located on chromosome 17q11.2 and consists of 14 exons spanning approximately 44 kb[5]. The protein product is a 630-amino acid sodium-dependent neurotransmitter transporter belonging to the SLC6A family. SERT shares structural features with other neurotransmitter transporters including:
SERT undergoes conformational changes during the transport cycle:
Within the brain, SERT is expressed in:
| Region | Expression Level | Cell Type |
|---|---|---|
| Dorsal raphe nucleus | Highest | Serotonergic neurons |
| Median raphe nucleus | High | Serotonergic neurons |
| Hippocampus | Moderate | Terminals |
| Cortex | Moderate | Terminals |
| Striatum | Moderate | Terminals |
| Thalamus | Low | Terminals |
SERT is also expressed in:
SERT operates with a stoichiometry of:
The transport cycle is electrogenic, with net positive charge movement.
SERT transports:
SERT does not transport:
SERT activity is dynamically regulated:
| Modification | Enzyme | Effect |
|---|---|---|
| Phosphorylation (Ser62) | PKC | Internalization |
| Phosphorylation (Ser276) | PKC | Activity modulation |
| Glycosylation | ER/Golgi | Surface targeting |
| Palmitoylation | Palmitoyltransferases | Membrane anchoring |
SERT interacts with several regulatory proteins:
SERT expression is regulated by:
SERT dysfunction is implicated in major depressive disorder[6]:
SERT polymorphisms are associated with anxiety-related traits[7]:
SERT variants have been linked to autism:
Serotonergic deficits are observed in AD:
The loss of serotonergic neurons contributes to:
SERT changes in PD include:
| Disorder | SERT Changes | Clinical Implications |
|---|---|---|
| FTD | Reduced binding | Depression |
| ALS | Variable | Mood effects |
| HD | Reduced binding | Psychiatric symptoms |
First-line treatments targeting SERT:
| Drug | Year | Half-life (h) | Notes |
|---|---|---|---|
| Fluoxetine | 1987 | 72 | Long half-life |
| Paroxetine | 1992 | 21 | Most potent |
| Sertraline | 1991 | 26 | Active metabolite |
| Citalopram | 1989 | 35 | Racemic |
| Escitalopram | 2002 | 27 | S-enantiomer |
| Fluvoxamine | 1992 | 15 | Short half-life |
SERT inhibitor side effects:
The serotonin transporter gene-linked polymorphic region (5-HTTLPR) is a common genetic variant:
| Allele | Length | Expression |
|---|---|---|
| S (short) | 44 bp | Lower expression |
| L (long) | 44 bp | Higher expression |
The S allele has been associated with:
SERT expression changes during development[8]:
SERT is regulated by neuronal activity:
SERT research employs:
Key models include:
The serotonin transporter (SERT) represents a critical hub in serotonergic neurotransmission, serving as both the primary mechanism for terminating synaptic signaling and as the principal target for widely prescribed antidepressant medications. SERT's function is dynamically regulated through multiple mechanisms including phosphorylation, trafficking, and protein interactions, and genetic variation in the SLC6A4 gene contributes to individual differences in mood, anxiety, and treatment response. Understanding SERT biology continues to inform both basic neuroscience and clinical psychiatry, with ongoing research exploring novel therapeutic approaches that target this important transporter.
SERT in psychiatric disorders. 2020. ↩︎
Neurobiology of depression. 2015. ↩︎
SERT and anxiety disorders. 2003. ↩︎
SERT in brain development. 2003. ↩︎